This part is a big surprise for me...
Just shows there is fundamental lack of understanding in the drug approval....
From a P3 results success to lunch, there is a 4x return...
post p3 success there is less than 5% chance the drug won't be launched ....
Launch is different to success of the drug in terms of uptake so let's not mix two things together....
We should be smashing $2 if we can get US and China deals across before end of this year as our market is way bigger than NEU..
and $5-$10 if we launch it..
This part is a big surprise for me...Just shows there is...
-
- There are more pages in this discussion • 210 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $280.6M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 54.5¢ | 51.0¢ | $1.715M | 3.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 365433 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 19658 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |